Clinical Research

BD Biosciences products support a broad range of immunophenotyping and intracellular staining reagents for blood cell disorders and tools for the study of cell cycle, proliferation, and cell death.

Oncology, the study of cancer, is a complex area of human disease with many challenges including heterogeneity of disease and limited samples. Throughout the world, BD Biosciences tools help clinical researchers study genes, proteins, and cells to better understand disease, improve diagnosis and disease management, and facilitate the discovery and development of novel therapeutics. BD Biosciences clinical oncology research solutions range from antibodies to cellular markers for isolation of specific subpopulations, and determination of cytokine expression, transcription factors, and phosphorylation status.

Blood Cell Disorder Research

BD Biosciences supports leukemia clinical research with a broad range of immunophenotyping reagents and tools for flow cytometric applications, supporting among others scientists who are studying the biological aspects of Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL).

The process of diagnosis, classification, treatment, and monitoring of leukemia and lymphoma patients is complex and continuously evolving.

Over the past years BD Biosciences has been working with several independent European Working Groups – i.e., ERIC, NOPHO, I-BFM – and independent Consortia in Europe, as well as in US, in the standardization of their processes. Standardization of processes improves the quality of results, and ultimately the diagnosis and treatment of leukemia patients.

In addition, BD Biosciences started to collaborate with the EuroFlow™ Consortium, a scientifically independent network, supported by the European Commission (grant LSHB-CT-2006-018708) for the specific targeted research project “Flow cytometry for fast and sensitive diagnosis and follow-up of hematological malignancies”.

As quoted by the EuroFlow Consortium "The 4-year project successfully met its primary objectives: development, standardization and validation of 8-color flow cytometric protocols for n-dimensional immunophenotyping of hematological malignancies, based on novel software and new strategies for design of antibody panels as well as the development and diagnostic evaluation of flow cytometric immunobead assays for fusion protein detection for classification of leukemia patients."

If you are interested to find out more or obtain more information about the EuroFlow Consortium and its project, please visit

Cell Cycle, Proliferation, and Cell Death Research

Cell cycle, proliferation, and cell death play important roles in development and tissue homeostasis. Apoptosis, or programmed cell death, is of particular importance in cancer research. The ability of cells to escape normal apoptotic pathways leads to a survival advantage for malignant cells. In contrast, too much apoptosis contributes to neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. BD Biosciences tools for the study of cell cycle, proliferation, and cell death include BD Pharmingen™ Annexin V kits, BD Phamingen BrdU kits, and antibodies to cyclins and activated caspases optimized for use on BD flow cytometry systems.